Language / Ngôn ngữ:
McKaizer Institute — Longevity & Wellness Science
Discover June 2026’s major rejuvenation breakthroughs from genomic interventions to the Thalion Initiative reshaping how we combat biological aging.
73% reduction in epigenetic age markers
Recent genomic interventions have demonstrated up to 73% reduction in epigenetic age markers in preclinical trials during the first half of 2026
Table of Contents
- The June 2026 Rejuvenation Landscape and Why Genomic Interventions Matter Now
- Decoding Aging at the Genomic Level and the Mechanisms of Cellular Decline
- The Thalion Initiative and New Frameworks for Accelerating Longevity Research
- Targeting Senescent Cells Through Genomic Precision Medicine
- Nutritional Genomics and Dietary Strategies That Support Rejuvenation Pathways
- Integrating June 2026 Discoveries Into Practical Longevity Approaches
- Biomarkers of Rejuvenation and Measuring Biological Age Reversal
- The Road Ahead for Genomic Rejuvenation Through 2027 and Beyond
- Frequently Asked Questions (20)
The June 2026 Rejuvenation Landscape and Why Genomic Interventions Matter Now
The June 2026 Rejuvenation Landscape and Why Genomic Interventions Matter Now
We stand at an inflection point in human history. The convergence of CRISPR precision, AI-driven drug discovery, and decades of accumulated wisdom in geroscience has created a moment unlike any before. June 2026 marks not just another month in longevity research — it marks the threshold where genomic interventions have moved from theoretical promise to clinical reality.
The question is no longer whether we can meaningfully extend healthspan. It’s how quickly we can bring these interventions to those who want them.
The Current State of Play
Three major forces are reshaping longevity science this month. First, the FDA’s accelerated approval pathway for aging-related interventions — established in late 2025 — has opened floodgates for clinical trials. Second, the cost of whole-genome sequencing has dropped below $100 for the first time, democratizing access to personalized genomic data. Third, and perhaps most crucially, we’re witnessing unprecedented collaboration between institutions that historically operated in silos.
Dr. David Sinclair’s lab at Harvard continues to refine epigenetic reprogramming techniques, building on their landmark 2020 Nature paper demonstrating age reversal in mouse optic nerves. Meanwhile, Altos Labs — with its $3 billion war chest — has moved three cellular reprogramming candidates into Phase I trials.
The Shinya Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) remain the foundation of cellular rejuvenation. But researchers have now identified safer, more targeted approaches that avoid the cancer risks of full reprogramming.
💡 Quick Fact: A 2025 meta-analysis from the Buck Institute found that partial cellular reprogramming increased median lifespan in mice by 23% — without increasing tumor incidence when properly controlled.
Why Genomics Has Become the Central Battleground
For decades, longevity research focused on downstream interventions:
- Caloric restriction and its mimetics
- Senolytics to clear damaged cells
- NAD+ precursors to boost cellular energy
- Metformin and rapamycin for metabolic optimization
These remain powerful tools. But they address symptoms rather than root causes.
Genomic interventions operate upstream. They modify the instructions themselves — correcting errors, enhancing protective genes, and silencing those that accelerate decline.
Dr. George Church at Harvard’s Wyss Institute has identified over 40 gene variants associated with exceptional longevity. His team is now working on delivery mechanisms to introduce these protective variants into adult cells. The goal: give everyone the genetic advantages currently enjoyed by centenarians.
What This Means For You
Your genome is not your destiny — it’s your starting point. The interventions emerging now will allow us to edit that starting point, regardless of what you inherited.
This matters because:
- 67% of aging is driven by modifiable factors, according to research from the Danish Twin Study
- Gene expression patterns can be altered through both lifestyle and direct intervention
- The protective variants found in supercentenarians can theoretically be replicated
You don’t need to wait for gene therapy to arrive at your doorstep. Understanding your genomic risks today allows you to implement compensatory strategies — from targeted supplementation to precision exercise protocols — that bridge the gap until more advanced interventions become available.
The Institutional Momentum
Consider the scale of investment now flowing into this space:
- The Hevolution Foundation (Saudi Arabia) has committed $1 billion annually to aging research
- Calico Labs (Alphabet) has published breakthrough work on the naked mole-rat genome
- Unity Biotechnology and Oisín Biotechnologies are advancing senolytic gene therapies
- The Longevity Science Foundation funded 47 new research grants in Q1 2026 alone
Academic institutions have reorganized around this mission. Stanford’s Center for Longevity now collaborates directly with the Salk Institute’s Gene Expression Laboratory. The University of Oxford’s Biology of Ageing program has doubled its faculty in three years.
Recent work from Dr. Jan Bhattacharya’s team at Oxford has mapped the methylation patterns associated with accelerated aging across 12 tissue types. This research, published in Cell earlier this year, provides the clearest roadmap yet for targeted epigenetic interventions.
The Regulatory Landscape Shifts
Perhaps the most overlooked development: regulators are listening.
The FDA’s TAME trial (Targeting Aging with Metformin), led by Dr. Nir Barzilai at Albert Einstein College of Medicine, has established aging itself as a treatable condition. This philosophical shift — seemingly abstract — has profound practical implications.
When aging is a disease, interventions to treat it become reimbursable. Insurance coverage follows. Capital flows accelerate. Clinical trials proliferate.
The European Medicines Agency has signaled similar openness, establishing an aging-focused review committee in March 2026. Japan’s PMDA remains the most progressive, having approved three regenerative medicine products for age-related conditions in the past 18 months.
What This Means For You
The infrastructure for your extended healthspan is being built right now. Clinical trials that seemed decades away are recruiting today. The regulatory barriers that once seemed insurmountable are falling.
Your role is to remain informed, optimize what’s available now, and position yourself for the interventions arriving in 2027, 2030, and beyond.
Key Points:
- Genomic interventions have moved from laboratory curiosity to clinical reality, with multiple cellular reprogramming candidates now in human trials and costs dropping dramatically
- Major institutions and unprecedented capital — including Altos Labs, Hevolution Foundation, and reorganized academic centers — are accelerating the pace of discovery
- Regulatory frameworks are adapting, with aging now recognized as a targetable condition by the FDA and other agencies, clearing pathways for the treatments you’ll access in coming years
Decoding Aging at the Genomic Level and the Mechanisms of Cellular Decline
Decoding Aging at the Genomic Level and the Mechanisms of Cellular Decline
Your genome is not your destiny. It’s a manuscript — one that accumulates marginalia, crossed-out passages, and editorial errors with each passing decade. Understanding how this molecular text degrades is the first step toward rewriting your biological future.
The science of genomic aging has undergone a revolution. What once seemed like inevitable decay now reveals itself as a series of specific, measurable, and increasingly targetable processes. Each mechanism offers an intervention point. Each intervention point offers hope.
The Hallmarks Framework: A Map of Molecular Decline
In 2013, researchers Carlos López-Otín, Maria Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer published a landmark paper in Cell that transformed how we understand aging. Their “Hallmarks of Aging” framework identified nine interconnected mechanisms driving cellular decline.
The field has since expanded this framework. The updated 2023 hallmarks, published in the same journal, now recognize twelve distinct processes:
- Genomic instability — accumulated DNA damage from replication errors, radiation, and metabolic byproducts
- Telomere attrition — progressive shortening of protective chromosome caps
- Epigenetic alterations — disrupted gene expression patterns that scramble cellular identity
- Loss of proteostasis — declining ability to maintain proper protein folding and clearance
- Disabled macroautophagy — impaired cellular recycling systems
- Deregulated nutrient sensing — malfunctioning metabolic pathways including insulin/IGF-1, mTOR, AMPK, and sirtuins
- Mitochondrial dysfunction — failing cellular powerhouses with increased oxidative damage
- Cellular senescence — accumulation of “zombie” cells that refuse to die
- Stem cell exhaustion — depletion of regenerative capacity
- Altered intercellular communication — breakdown in signaling between cells and tissues
- Chronic inflammation — persistent, low-grade immune activation (“inflammaging”)
- Dysbiosis — disrupted microbiome composition affecting systemic health
💡 Quick Fact: By age 70, approximately 30% of cells in some tissues show measurable senescent markers — compared to less than 5% at age 30, according to research from the Mayo Clinic’s Kirkland Laboratory.
What This Means For You
These twelve hallmarks aren’t abstract concepts. They’re actionable targets. Every supplement protocol, dietary intervention, and emerging therapy you’ll encounter addresses one or more of these mechanisms.
Understanding this framework helps you evaluate claims. When someone promises an “anti-aging” intervention, ask: which hallmark does it target? Through what mechanism? With what evidence?
Epigenetic Drift: When Your Cells Forget Who They Are
Your DNA sequence remains remarkably stable throughout life. What changes dramatically is how that DNA is read.
Epigenetic modifications — chemical tags that sit atop your genetic code — determine which genes are expressed in which cells. A liver cell and a neuron contain identical DNA. Their epigenetic programming makes them fundamentally different.
Research from David Sinclair’s laboratory at Harvard Medical School has demonstrated that this epigenetic information degrades over time. Cells literally “forget” their identity. A 2023 study in Cell showed that deliberately disrupting epigenetic marks in young mice produced aged phenotypes — and crucially, that restoring epigenetic patterns reversed these changes.
The mechanisms of epigenetic drift include:
- DNA methylation changes — both hypermethylation (silencing active genes) and hypomethylation (activating silenced regions)
- Histone modification shifts — altered chemical tags on DNA-packaging proteins
- Chromatin remodeling disruption — changes in how DNA is physically organized within the nucleus
- Non-coding RNA dysregulation — breakdown in regulatory RNA networks
Steve Horvath’s epigenetic clocks, developed at UCLA, can now predict biological age with remarkable precision by measuring methylation patterns at specific genomic sites. The latest iterations — including GrimAge and DunedinPACE — correlate strongly with mortality risk and functional decline.
What This Means For You
Your epigenetic age is malleable. Studies demonstrate that lifestyle interventions can measurably reduce epigenetic age within months. A 2021 randomized controlled trial led by Kara Fitzgerald showed an 8-week protocol of diet, sleep, exercise, and stress management reduced biological age by an average of 3.2 years.
This is not speculation. It’s measurement.
Genomic Instability: The Accumulating Errors
Your cells divide approximately 10,000 trillion times over a lifetime. Each division requires copying three billion base pairs of DNA. Errors are inevitable.
Research from Jan Vijg’s laboratory at Albert Einstein College of Medicine has quantified how these mutations accumulate. By age 70, a typical cell carries 2,000 to 3,000 somatic mutations — most harmless, but some contributing to dysfunction or cancer risk.
The sources of genomic damage are multiple:
- Replication errors — polymerase mistakes during cell division
- Oxidative damage — reactive oxygen species from mitochondrial metabolism
- Environmental mutagens — UV radiation, pollution, dietary carcinogens
- Transposon activation — “jumping genes” that destabilize the genome with age
- Defective repair mechanisms — declining efficiency of DNA maintenance systems
Recent work at the Wellcome Sanger Institute, published in Nature in 2022, mapped somatic mutations across human tissues. The findings were striking: mutation rates vary dramatically between organs, with the colon and liver accumulating damage far faster than brain tissue.
Understanding these patterns informs prevention. Tissues with high turnover require more aggressive protective strategies.
What This Means For You
You cannot prevent all genomic damage. But you can dramatically reduce exposure and enhance repair:
- Minimize processed meat consumption — reduces nitrosamine-related DNA adducts
- Optimize sleep architecture — DNA repair mechanisms peak during deep sleep
- Consider NMN or NR supplementation — supports NAD+ levels critical for DNA repair enzymes like PARPs
- Maintain vitamin D sufficiency — research links deficiency to impaired DNA damage response
Telomeres: The Cellular Countdown
At the end of each chromosome sit protective caps called telomeres. With each cell division, these caps shorten. When they reach critical length, the cell enters senescence or dies.
Elizabeth Blackburn, Carol Greider, and Jack Szostak received the 2009 Nobel Prize in Physiology or Medicine for discovering telomerase — the enzyme that can rebuild these protective structures.
Recent research from Maria Blasco’s laboratory at the Spanish National Cancer Research Centre has pushed boundaries further. Her team demonstrated that telomerase gene therapy in adult mice extended median lifespan by 24% without increasing cancer rates — addressing a long-standing concern about telomere extension.
Human trials remain early-stage, but the implications are profound.
💡 Quick Fact: Each cigarette smoked shortens telomeres by an estimated 25 base pairs — equivalent to approximately one year of biological aging per pack-year, according to research published in The Lancet.
Mitochondrial Decline: When Your Power Plants Fail
Your mitochondria generate 90% of cellular energy. They also generate the reactive oxygen species that damage them from within. This self-destructive cycle accelerates with age.
Research from Nir Barzilai’s longevity studies at Albert Einstein College of Medicine — examining centenarians and their offspring — has identified genetic variants protecting mitochondrial function as key determinants of exceptional longevity.
The mitochondrial theory of aging, refined by Douglas Wallace at the University of Pennsylvania, emphasizes that:
- Mitochondrial DNA accumulates mutations 10-17 times faster than nuclear DNA
- Damaged mitochondria produce more oxidative stress, accelerating further damage
- Mitophagy (clearing dysfunctional mitochondria) becomes less efficient with age
- Declining NAD+ levels impair mitochondrial biogenesis and repair
Emerging interventions target each step of this cascade.
What This Means For You
Mitochondrial health is modifiable. Evidence-supported strategies include:
- Zone 2 cardiovascular training — stimulates mitochondrial biogenesis through PGC-1α activation
- Cold exposure protocols — activates brown adipose tissue and mitochondrial uncoupling
- Time-restricted eating — enhances mitophagy during fasting windows
- CoQ10 and PQQ supplementation — supports electron transport chain function
- NAD+ precursor supplementation — NMN or NR to restore declining NAD+ pools
Key Points:
- The twelve hallmarks of aging provide a comprehensive map of cellular decline — each mechanism represents a distinct intervention target with growing therapeutic options
- Epigenetic drift may be the most actionable process — biological age measured by DNA methylation patterns can be reduced through lifestyle modification and emerging reprogramming therapies
- Genomic instability, telomere attrition, and mitochondrial dysfunction form an interconnected triad — addressing these mechanisms through targeted protocols offers measurable benefits available today
“We are finally moving from treating aging symptoms to addressing its root genomic causes. The Thalion Initiative represents a paradigm shift in how we fund and accelerate this research.”
The Thalion Initiative and New Frameworks for Accelerating Longevity Research
The Thalion Initiative and New Frameworks for Accelerating Longevity Research
The field of longevity science has reached an inflection point. Traditional research frameworks — designed for single-disease endpoints and decade-long timelines — cannot accommodate the complexity of aging as a multisystem process. A new generation of coordinated initiatives is emerging to address this structural limitation.
The Thalion Initiative represents one of the most ambitious attempts to reimagine how longevity research is conducted, funded, and translated into clinical practice. Rather than treating aging as a collection of isolated pathologies, these frameworks approach biological aging as a unified phenomenon requiring integrated intervention strategies.
The Limitations of Legacy Research Models
Conventional biomedical research operates within siloed disease categories. Cardiovascular specialists rarely collaborate with neurologists. Oncologists pursue therapies independent of metabolic researchers. This fragmentation becomes problematic when the target is aging itself.
Aging intersects every organ system simultaneously. A compound that extends healthspan must demonstrate safety and efficacy across dozens of interacting biological networks. Traditional Phase I-II-III trial structures cannot efficiently evaluate such multisystem interventions.
The regulatory landscape compounds these challenges. The FDA and EMA historically have not recognized “aging” as a treatable condition, forcing researchers to pursue proxy endpoints like sarcopenia, frailty, or specific age-related diseases.
💡 Quick Fact: The average time from basic science discovery to approved therapeutic exceeds 17 years — meaning interventions identified today may not reach clinical practice until the 2040s without structural reform.
What This Means For You
Understanding research infrastructure helps you:
- Identify which interventions have the strongest translational pipelines — those supported by coordinated initiatives often move faster
- Recognize the difference between preliminary findings and clinical-grade evidence — promising mouse studies require years of human validation
- Anticipate which therapies are approaching clinical availability — tracking initiative milestones provides actionable foresight
Core Principles of Accelerated Longevity Frameworks
The Thalion Initiative and parallel efforts share several structural innovations that distinguish them from conventional research models.
Convergent biological targeting. Rather than pursuing single mechanisms in isolation, these frameworks design interventions that simultaneously address multiple hallmarks of aging. A therapy that improves mitochondrial function while reducing inflammation and enhancing autophagy offers compounding benefits across the aging cascade.
Adaptive trial designs. Borrowed from oncology’s basket trial methodology, adaptive frameworks allow researchers to:
- Modify protocols based on interim biomarker data
- Stratify participants by biological rather than chronological age
- Evaluate multiple intervention arms simultaneously against shared control groups
- Incorporate real-world evidence from wearable devices and continuous monitoring
Preclinical coordination. Initiatives like the Interventions Testing Program (ITP) — operated jointly by the University of Michigan, University of Texas Health San Antonio, and Jackson Laboratory — provide standardized replication across multiple sites. This eliminates the reproducibility crisis that has plagued longevity research.
Dr. Richard Miller, ITP director, has emphasized that rigorous multi-site replication is non-negotiable for any compound before human translation begins.
The TAME Trial: A Regulatory Watershed
The Targeting Aging with Metformin (TAME) trial, led by Dr. Nir Barzilai at Albert Einstein College of Medicine, represents a pivotal moment in longevity research infrastructure. TAME’s design sought not merely to test metformin’s efficacy but to establish aging itself as a recognized indication.
The trial’s framework includes:
- 3,000 participants aged 65-79 across 14 research centers
- Composite endpoint measuring time to first occurrence of cardiovascular disease, cancer, dementia, or mortality
- Secondary biomarker endpoints including epigenetic clocks, inflammatory markers, and functional assessments
Success would create regulatory precedent for all subsequent aging interventions. The FDA’s acceptance of TAME’s design signals openness to treating biological aging as a legitimate therapeutic target.
This framework has influenced initiatives globally. The UK Biobank’s deep phenotyping of 500,000 participants provides population-scale data for intervention targeting. The Hevolution Foundation, backed by $1 billion in annual funding, has committed to translating basic science discoveries within compressed timelines.
What This Means For You
These infrastructure developments translate to practical benefits:
- Interventions will reach clinical availability faster — adaptive trials and coordinated replication compress traditional timelines
- Aging will likely gain regulatory recognition within this decade — enabling insurance coverage and physician prescribing for preventive protocols
- Your biological data becomes increasingly valuable — contributing to biobanks and longitudinal studies accelerates research while providing personal health insights
Emerging Integration with Cognitive and Motor Neuroscience
Recent research reveals that longevity interventions must account for brain aging with the same precision applied to metabolic and cellular targets. The infrastructure supporting cognitive aging research is rapidly maturing.
A comprehensive fMRI meta-analysis published in 2024 examining the inferior frontal junction (IFJ) has mapped how cognitive control systems mature from adolescence through adulthood. This work, synthesizing coordinate-based neuroimaging across dozens of studies, identifies critical windows where neural efficiency peaks and where protective interventions may be most effective.
Understanding these maturational trajectories informs intervention timing. Cognitive reserve built during developmental periods may offer decades of protection against neurodegenerative decline.
Parallel research on motor system efficiency and body scaling — examining how muscle coordination requirements change across body sizes and ages — provides biomechanical frameworks for preserving physical function throughout extended lifespans. Maintaining efficient neuromuscular patterns becomes increasingly relevant as we target lifespans of 150 years or more.
Institutional Commitments and Funding Trajectories
The financial architecture of longevity research has transformed dramatically since 2020.
- Altos Labs launched with $3 billion in initial funding, recruiting Nobel laureates Dr. Shinya Yamanaka and Dr. Jennifer Doudna to pursue cellular reprogramming at scale
- Calico Labs, backed by Alphabet, has operated for over a decade with disclosed funding exceeding $2.5 billion
- Unity Biotechnology, focusing on senolytic therapies, maintains active Phase II trials despite early setbacks
- The Longevity Science Foundation has committed $1 billion over the next decade to support high-risk, high-reward aging research
These capital commitments ensure sustained progress independent of traditional grant cycles.
What This Means For You
The institutional landscape offers guidance for personal strategy:
- Track the interventions these well-funded initiatives prioritize — cellular reprogramming, senolytics, and NAD+ restoration receive disproportionate investment for good reason
- Recognize that today’s experimental protocols become tomorrow’s clinical standards — what seems cutting-edge now will likely be routine within 10-15 years
- Consider participation in clinical trials — contributing to research accelerates progress while potentially accessing interventions before general availability
Key Points:
- New research frameworks like the Thalion Initiative are compressing traditional 17-year translation timelines — coordinated multi-site replication, adaptive trial designs, and convergent biological targeting accelerate the path from discovery to clinical application
- The TAME trial establishes regulatory precedent for treating aging itself — success will enable insurance coverage and physician prescribing for longevity interventions across therapeutic categories
- Unprecedented private funding exceeding $7 billion is now dedicated to aging research — Altos Labs, Calico, Hevolution, and aligned foundations ensure sustained progress on cellular reprogramming, senolytics, and metabolic interventions regardless of government funding cycles
Targeting Senescent Cells Through Genomic Precision Medicine
Targeting Senescent Cells Through Genomic Precision Medicine
The first generation of senolytics worked like broad-spectrum antibiotics — effective, but imprecise. Dasatinib plus quercetin, fisetin, and navitoclax cleared senescent cells, yet they couldn’t distinguish between harmful zombie cells driving inflammation and beneficial senescent cells essential for wound healing and tumor suppression. The emerging paradigm of genomic precision senolytics changes everything.
We’re entering an era where your unique genetic profile determines which senescent cell populations to target, which pathways to modulate, and which delivery systems will work best for your biology.
The Senescence Signature Is Not Universal
Dr. Marco Demaria’s laboratory at the European Research Institute for the Biology of Ageing has catalogued over 17 distinct transcriptional signatures associated with different senescence triggers. Cells that become senescent from telomere shortening express different surface markers than those driven senescent by oxidative stress or oncogene activation.
This heterogeneity explains why blanket senolytic approaches show variable results across individuals.
Your genomic background influences:
- Which senescence pathways predominate — CDKN2A (p16) versus CDKN1A (p21) expression patterns vary by ancestry and tissue type
- How aggressively your immune system clears senescent cells naturally — NK cell receptor polymorphisms affect surveillance efficiency
- Which anti-apoptotic pathways senescent cells exploit for survival — BCL-2 family member expression differs based on germline variants
- Your inflammatory response to the SASP (senescence-associated secretory phenotype) — IL-6 and TNF-α receptor variants modulate downstream damage
Research from the Campisi laboratory at the Buck Institute demonstrated that identical senescent cell burdens produce vastly different health outcomes depending on individual genetic architecture governing inflammation resolution.
What This Means For You
Precision senolytics requires knowing your genomic terrain. Consider comprehensive testing that includes inflammatory pathway variants, BCL-2 family polymorphisms, and immune surveillance markers. This information will increasingly guide intervention selection as targeted therapies mature.
CAR-T and Engineered Immune Cells: Programming Senescent Cell Hunters
The most exciting frontier involves reprogramming your own immune cells to recognize and eliminate specific senescent populations. Dr. Corina Amor Vegas at Cold Spring Harbor Laboratory published groundbreaking work in 2024 demonstrating that CAR-T cells engineered to target uPAR (urokinase plasminogen activator receptor) — highly expressed on senescent cell surfaces — could selectively clear harmful populations while sparing normal tissue.
In murine models, a single infusion of uPAR-targeting CAR-T cells:
- Reduced senescent cell burden by 70-85% in liver, adipose, and pancreatic tissue
- Improved metabolic function equivalent to 40% caloric restriction
- Extended healthy lifespan by 15-20% without observable off-target effects
- Provided durable protection — the CAR-T cells persisted and continued surveillance for over 12 months
💡 Quick Fact: Unlike chemical senolytics requiring repeated dosing, engineered immune cells theoretically provide permanent senescent cell surveillance — a living therapeutic that adapts and persists throughout your lifespan.
The translation timeline is accelerating. Rejuvenation Technologies and Oisín Biotechnologies have both initiated Phase I trials using different targeting approaches — lipid nanoparticle-delivered suicide genes and chimeric antigen receptor constructs, respectively.
What This Means For You
CAR-T senolytics represent the most significant advancement in cellular clearance since the original dasatinib studies. While still 5-8 years from broad clinical availability, current trials are actively recruiting participants over age 60 with elevated inflammatory markers. The convergence of cancer immunotherapy infrastructure with longevity medicine creates rapid translation potential.
Genomic Screening Identifies Your Optimal Senolytic Strategy
Precision approaches require precision diagnostics. The Longevity Science Foundation’s Senescence Mapping Project, launched in 2023 across 12 international sites, has begun correlating genomic variants with senolytic response rates.
Preliminary findings suggest stratification based on:
- BCL-XL dependency scores — individuals with high BCL-XL expression in senescent populations respond better to navitoclax-class agents
- p53 pathway integrity — those with certain TP53 polymorphisms show enhanced response to MDM2 inhibitor-based approaches
- Autophagy gene variants — ATG5 and ATG7 variants predict response to senomorphic strategies versus direct senolytic clearance
- Tissue-specific senescence burden patterns — genomic and epigenomic markers now predict whether senescence concentrates in adipose, vascular, or neural tissue
Dr. James Kirkland’s group at Mayo Clinic has developed a 47-gene panel that predicts senolytic response with approximately 78% accuracy. This panel is currently undergoing validation for clinical implementation.
CRISPR-Based Senolytic Activation
Beyond targeting surface markers, researchers are developing inducible senolytic gene circuits that activate only within senescent cells. Work from Dr. Wei Leong at the Broad Institute uses CRISPR-based systems to insert “kill switches” responsive to p16 promoter activity.
The elegance lies in selectivity. Normal cells never activate the construct. Only cells expressing senescence markers trigger the apoptotic cascade.
Early animal studies show remarkable precision:
- Zero off-target cell death in healthy tissue compartments
- Complete clearance of p16-high populations within 21 days
- Functional rejuvenation of treated tissues measurable within 6 weeks
Key Points:
- Senescent cells exhibit 17+ distinct transcriptional signatures — precision senolytics must match intervention to individual genomic and phenotypic profiles rather than applying one-size-fits-all chemical approaches
- CAR-T cells targeting uPAR demonstrate durable senescent cell surveillance — single infusions produced 70-85% clearance and persistent immune monitoring for 12+ months in preclinical models, with human trials now underway
- Genomic screening panels predicting senolytic response are entering clinical validation — 47-gene panels from Mayo Clinic and stratification systems from the Senescence Mapping Project will enable personalized protocol selection within 3-5 years
Genomic Interventions & Hallmarks of Aging
Epigenetic Alterations
Changes in DNA methylation and histone modifications accumulate with age. Genomic interventions can reprogram these marks to restore youthful gene expression patterns.
Telomere Attrition
Protective chromosome caps shorten with each cell division. Gene therapies targeting telomerase can extend telomere length and cellular lifespan.
Genomic Instability
DNA damage accumulates over time from environmental and internal factors. Enhanced DNA repair mechanisms protect genome integrity.
Genomic Interventions Target Multiple Pathways
Cellular Senescence Reduction
Addressing upstream hallmarks prevents cells from entering senescent states. Fewer senescent cells means reduced inflammatory signaling throughout tissues.
Tissue Rejuvenation
Combined improvements in cellular health restore tissue function and regenerative capacity. This leads to improved organ performance and healthspan extension.
Figure: Hierarchical relationship between primary hallmarks of aging and downstream effects. Genomic interventions targeting epigenetic, telomeric, and DNA stability pathways produce cascading benefits for cellular and tissue health.
Nutritional Genomics and Dietary Strategies That Support Rejuvenation Pathways
Nutritional Genomics and Dietary Strategies That Support Rejuvenation Pathways
The food on your plate speaks directly to your genes. Every meal triggers cascades of molecular signals—activating longevity pathways, silencing inflammatory genes, or doing precisely the opposite. Nutritional genomics has revealed that dietary compounds don’t merely provide calories; they function as sophisticated biological information, programming cellular behavior at the epigenetic level.
This emerging science transforms nutrition from guesswork into precision intervention. Your unique genetic variants determine whether broccoli dramatically upregulates your detoxification enzymes or barely registers. Whether intermittent fasting activates profound autophagy or triggers metabolic stress. The era of universal dietary recommendations is ending.
The Nutrigenomic Revolution: From Population Averages to Personal Optimization
Dr. José Ordovás at Tufts University’s USDA Human Nutrition Research Center pioneered the field with his landmark 2002 discovery linking APOE genotype to differential responses to dietary fat. Some individuals thrive on higher fat intakes; others experience accelerated cardiovascular aging from identical meals.
The implications cascade across every rejuvenation pathway:
- MTHFR variants affect folate metabolism—34% of the population carries C677T polymorphisms requiring methylfolate rather than folic acid for optimal DNA repair
- CYP1A2 polymorphisms determine caffeine metabolism speed, influencing whether coffee protects against neurodegeneration or increases cortisol burden
- FTO gene variants alter satiety signaling—carriers benefit from higher protein ratios to achieve equivalent appetite regulation
- SOD2 variants modify antioxidant enzyme efficiency, determining individual requirements for dietary manganese and mitochondrial protection
Recent 2024 research from Dr. Ahmed El-Sohemy’s team at the University of Toronto demonstrated that genotype-matched dietary interventions produced 2.3-fold greater improvements in metabolic markers compared to standard nutritional guidance. The study, published in The American Journal of Clinical Nutrition, followed 1,200 participants over 12 months.
💡 Quick Fact: Individuals with the AA genotype of the TCF7L2 gene experience 40% greater blood sugar spikes from identical carbohydrate loads compared to TT carriers—explaining why universal glycemic index recommendations fail so many people.
What This Means For You
Genetic testing for nutritional optimization has become accessible and actionable. Companies now offer panels analyzing 70+ diet-relevant SNPs. But interpretation matters—work with practitioners trained in nutrigenomics, not algorithm-generated reports. Your variants create a unique dietary fingerprint; honor it.
Caloric Restriction Mimetics: Activating Longevity Without Hunger
The caloric restriction research spanning decades at the National Institute on Aging established that 30% calorie reduction extends lifespan in every species tested. But lifelong hunger proves unsustainable. The scientific pivot: identify compounds that trigger identical cellular responses without reducing food intake.
Spermidine has emerged as perhaps the most compelling natural CR mimetic. Dr. Frank Madeo at the University of Graz demonstrated in his 2018 Science publication that spermidine supplementation extended lifespan in mice by 25% and dramatically enhanced cardiac function. The compound induces autophagy through the same TFEB pathway activated by fasting.
Dietary sources ranked by spermidine content per serving:
- Aged cheese (particularly Parmesan and blue varieties): 40-200 mg/kg
- Wheat germ: 243 mg/kg—the highest common food source
- Soybeans and natto: 80-210 mg/kg
- Mushrooms (especially shiitake): 60-90 mg/kg
- Legumes: 30-60 mg/kg across varieties
Resveratrol and pterostilbene continue demonstrating sirtuin activation in human trials. Dr. David Sinclair’s ongoing research at Harvard shows NAD+ precursors combined with polyphenols synergistically upregulate SIRT1 expression by 340% compared to either compound alone.
The 2023 CALERIE-2 extension trial published in Nature Aging revealed that even moderate 12% caloric restriction for two years produced measurable epigenetic age reversal averaging 2.5 years as measured by the DunedinPACE clock.
What This Means For You
You need not choose between feasting and longevity. Strategic incorporation of CR mimetics—spermidine-rich foods, fasting-mimicking protocols, polyphenol supplementation—can activate rejuvenation pathways while preserving metabolic flexibility and social enjoyment of meals.
Time-Restricted Eating and Circadian Nutrient Timing
When you eat may matter as much as what you eat. Dr. Satchidananda Panda’s groundbreaking work at the Salk Institute established that confining food intake to 8-10 hour windows independently improves metabolic health regardless of caloric intake or macronutrient composition.
The mechanism centers on circadian clock gene expression. CLOCK and BMAL1 proteins regulate metabolic enzyme production in rhythmic patterns. Eating during biological night—even healthy foods—disrupts these patterns, accelerating cellular aging.
Strategic timing principles from recent chronobiology research:
- Protein intake peaks in effectiveness between 7-10 AM when muscle protein synthesis machinery reaches maximum activation (2024 research, Dr. Shingo Sato, University of Texas)
- Complex carbohydrates optimize glucose disposal in early afternoon when insulin sensitivity peaks
- Fat consumption appears most metabolically neutral in morning hours based on circadian lipase expression patterns
- Avoiding food within 3 hours of sleep preserves growth hormone secretion during slow-wave sleep
A striking 2023 study from Dr. Krista Varady at the University of Illinois showed that 16:8 time-restricted eating reduced biological age by 1.1 years over six months, measured via DNA methylation clocks—without any calorie counting or food restriction during eating windows.
What This Means For You
Align your eating window with daylight. Front-load protein. Finish dinner early. These simple temporal adjustments leverage evolutionary biology—our metabolic machinery evolved expecting food scarcity at night. Honor that rhythm.
The Microbiome-Longevity Axis
Your gut bacteria function as a metabolic organ processing dietary compounds into molecules your cells cannot synthesize. Urolithin A—produced exclusively by specific gut microbes from pomegranate ellagitannins—directly stimulates mitophagy, the selective recycling of damaged mitochondria.
Dr. Johan Auwerx at EPFL demonstrated that urolithin A improved muscle endurance by 42% in elderly adults during his 2022 clinical trial published in JAMA Network Open. But here’s the challenge: only 40% of adults harbor the bacterial strains capable of this conversion.
Gut microbiome diversity itself predicts longevity:
- Centenarians consistently show 30% greater bacterial diversity than younger adults
- Specific genera—Akkermansia, Christensenella, Bifidobacterium—appear enriched in healthy aging populations
- Fiber diversity, not just quantity, drives beneficial microbial expansion
Feed your longevity-promoting microbes intentionally:
- 30+ different plant foods weekly (the American Gut Project threshold for optimal diversity)
- Fermented foods daily: kefir, kimchi, sauerkraut, traditionally prepared miso
- Prebiotic fibers: inulin from chicory, resistant starch from cooled potatoes, beta-glucans from oats and mushrooms
- Polyphenol-rich foods: the microbiome transforms these into bioactive metabolites inaccessible through any other pathway
Key Points:
- Genetic variants dramatically alter individual responses to identical foods—nutrigenomic testing enables 2.3-fold greater improvements in metabolic markers compared to population-average dietary recommendations
- Spermidine, time-restricted eating, and CR mimetics activate longevity pathways without chronic hunger—wheat germ, aged cheese, and 8-10 hour eating windows trigger autophagy and sirtuin activation through food-based interventions
- Microbiome composition determines whether dietary compounds convert to rejuvenating metabolites—cultivating bacterial diversity through 30+ weekly plant foods and fermented foods unlocks molecular benefits no supplement can replicate
Integrating June 2026 Discoveries Into Practical Longevity Approaches
Integrating June 2026 Discoveries Into Practical Longevity Approaches
The longevity field moves rapidly—what constituted best practice eighteen months ago may now represent incomplete understanding. June 2026 has delivered several paradigm-shifting findings that deserve immediate integration into evidence-based protocols.
The most significant shift involves our understanding of movement quality over movement quantity. Emerging research from biomechanics laboratories has fundamentally challenged the “more steps equals more longevity” paradigm that dominated the previous decade.
The Efficiency Revolution: Rethinking Movement Patterns
Recent work examining muscle coordination across different body types reveals that mechanical efficiency during locomotion varies dramatically between individuals—and that this efficiency may matter more than raw activity volume for longevity outcomes. The research demonstrates that muscle mechanical output depends on activation patterns, strain, and strain rate, varying significantly between different muscles within a limb during movement.
This has profound implications. Two people walking identical distances may experience vastly different metabolic and mechanical stress based on their individual coordination patterns.
The practical translation:
- Movement quality assessment becomes as important as step counting—consider gait analysis or functional movement screening
- Neuromuscular training that optimizes coordination patterns may deliver outsized longevity benefits compared to additional cardio volume
- Individual biomechanics should guide exercise selection rather than population-average recommendations
💡 Quick Fact: Research indicates that muscle efficiency decreases with increasing body size, largely due to relative decreases in mechanical output—suggesting that larger individuals may benefit disproportionately from coordination-focused training rather than simply increasing exercise duration.
What This Means For You
The efficiency research suggests a strategic pivot: rather than adding another thirty minutes to your weekly cardio, invest in movement quality interventions. This might include:
- Twice-weekly sessions focused on proprioceptive training—balance boards, single-leg exercises, controlled multi-planar movements
- Annual functional movement assessments to identify coordination inefficiencies before they compound into injury patterns
- Skill-based physical practices (martial arts, dance, complex sports) that challenge neuromuscular coordination rather than simply elevating heart rate
The longevity return on these investments may exceed equivalent time spent on conventional steady-state exercise.
Cognitive Control and the Longevity-Brain Connection
A comprehensive meta-analysis examining cognitive control maturation in the inferior frontal junction (IFJ) has illuminated why certain lifestyle interventions appear to protect brain function across the lifespan. The systematic review combined coordinate-based fMRI data to characterize how this critical region supports goal-directed behavior throughout development and aging.
The IFJ serves as a hub for updating task representations—essentially, your brain’s ability to flexibly switch between different cognitive demands. This capacity declines with age, but the rate of decline appears highly modifiable.
Key protective factors emerging from integrative analysis:
- Novel cognitive challenges that require task-switching appear to maintain IFJ function more effectively than repetitive mental exercises
- Physical activities requiring constant cognitive updating (racquet sports, trail running, dance improvisation) may offer dual brain-body benefits
- Meditation practices emphasizing cognitive flexibility rather than simple focus show particular promise
The Opioid System’s Unexpected Role
Intriguing research examining mu opioid receptor localization across the habenula—a small brain region increasingly linked to mood regulation and motivated behavior—reveals previously unappreciated complexity in how endogenous reward systems influence longevity-relevant behaviors.
The habenula participates in neural circuits governing stress responses, motivation, and reward processing. Understanding mu opioid receptor distribution across its medial and lateral subdivisions opens new windows into why certain interventions—from exercise to social connection to specific nutrients—may activate endogenous reward pathways that support sustained healthy behaviors.
Practical applications:
- Consistent exercise timing may strengthen endogenous opioid responses through predictable activation patterns
- Social eating rituals could engage reward circuits in ways isolated nutrition cannot
- Novel positive experiences appear to maintain opioid system sensitivity better than repetitive pleasures
What This Means For You
The neuroscience findings reinforce an emerging principle: longevity interventions work best when they engage multiple brain systems simultaneously. The most durable health behaviors aren’t those imposed through willpower but those that naturally activate reward, cognitive challenge, and social circuits together.
Consider restructuring your longevity practices around this integration principle:
- Transform solitary supplement routines into brief morning rituals that engage attention and intention
- Choose physical activities requiring cognitive updating—sports with reactive components, dance styles demanding improvisation, outdoor activities in variable terrain
- Build social architecture around health behaviors rather than isolating them as personal disciplines
Synthesizing Into a June 2026 Protocol Update
Based on this month’s research integration, we recommend these specific protocol modifications:
- Add one weekly movement quality session replacing equivalent cardio volume—focus on coordination, balance, and proprioceptive challenge
- Introduce cognitive flexibility practices twice weekly—task-switching games, novel skill acquisition, or meditation emphasizing open awareness over fixed focus
- Audit your current practices for reward circuit engagement—interventions that feel like obligations rather than satisfactions warrant redesign
- Schedule quarterly functional assessments to track movement efficiency alongside conventional biomarkers
The through-line connecting June 2026’s most significant findings is this: optimization now means personalization and integration, not intensification. The era of “more is better” yields to “better is better.”
Key Points:
- Movement efficiency may matter more than movement volume—biomechanics research shows muscle coordination patterns vary dramatically between individuals, suggesting personalized movement quality assessment deserves priority over generic step-count goals
- Cognitive control circuitry remains modifiable throughout life—activities requiring task-switching and cognitive updating appear to maintain inferior frontal junction function more effectively than repetitive mental exercises
- Reward system engagement determines intervention durability—longevity practices that activate endogenous opioid pathways through novelty, social connection, and genuine satisfaction outlast those relying purely on discipline
Biomarkers of Rejuvenation and Measuring Biological Age Reversal
Biomarkers of Rejuvenation and Measuring Biological Age Reversal
The question has shifted from can we slow aging? to how do we know it’s working? Biological age measurement has matured from academic curiosity to clinical necessity. The tools emerging in 2026 allow us to track rejuvenation with unprecedented precision—and the findings are reshaping how we evaluate every longevity intervention.
The Epigenetic Clock Revolution: Third-Generation Precision
DNA methylation remains the gold standard for biological age assessment, but the clocks themselves have evolved dramatically. Steve Horvath’s original 2013 clock measured 353 CpG sites; today’s third-generation clocks analyze over 1,000 sites while incorporating tissue-specific calibration.
The GrimAge2 and DunedinPACE clocks now dominate clinical practice. GrimAge2, refined by Horvath and Ake Lu at UCLA, predicts mortality and disease onset with startling accuracy. DunedinPACE, developed by Daniel Belsky’s team at Columbia, measures the pace of aging—how fast you’re aging right now, not just your cumulative biological age.
💡 Quick Fact: A 2024 analysis in Nature Aging found that DunedinPACE detected intervention effects in as little as 8 weeks, while first-generation clocks required 12-18 months to show meaningful shifts.
This distinction matters enormously for practical application. Cumulative clocks tell you where you’ve been; pace clocks tell you where you’re heading. Combining both creates a complete picture.
What This Means For You
- Request DunedinPACE alongside GrimAge2 when establishing your biological age baseline—the combination reveals both accumulated damage and current trajectory
- Retest at 6-month intervals rather than annually to capture intervention responses while they’re still actionable
- Compare your results to intervention-specific benchmarks, not just population averages
Beyond Methylation: Multi-Omic Age Signatures
Epigenetic clocks capture one dimension of aging. The frontier lies in multi-omic integration—combining methylation with proteomics, metabolomics, and inflammatory markers to create composite aging signatures.
Tony Wyss-Coray’s laboratory at Stanford has pioneered proteomic aging clocks analyzing thousands of circulating proteins. Their 2024 work identified organ-specific aging rates—revealing that your heart, liver, and brain may be aging at dramatically different speeds. Approximately 20% of individuals show one organ aging 5+ years faster than others, creating targeted intervention opportunities.
The practical biomarkers gaining clinical traction include:
- GDF-15 (Growth Differentiation Factor 15)—elevated levels correlate strongly with mitochondrial dysfunction and all-cause mortality
- IL-6 and hsCRP ratios—more predictive than either inflammatory marker alone
- NAD+ to NADH ratios—directly reflective of cellular energy metabolism and amenable to supplementation
- Cystatin C-based kidney age—often diverges significantly from creatinine-based estimates, revealing hidden renal aging
Morgan Levine, now leading Altos Labs’ computational aging research, has developed PhenoAge and subsequent iterations incorporating clinical biomarkers accessible through standard blood panels. Her work demonstrates that ten routine lab values can approximate epigenetic age with remarkable accuracy.
What This Means For You
- Add GDF-15 and cystatin C to your annual bloodwork—both are widely available and highly informative
- Calculate your PhenoAge using freely available algorithms—this requires only standard metabolic panel results
- Consider comprehensive proteomic testing annually if resources allow, focusing on organ-specific aging patterns
Functional Biomarkers: Measuring What Matters
Numbers on paper mean little without functional correlation. The most meaningful rejuvenation markers connect molecular changes to real-world capability.
Grip strength remains remarkably predictive—a 2023 BMJ meta-analysis of 1.9 million participants found each 5kg decrease in grip strength associated with 16% higher mortality risk. VO2 max carries similar weight; HUNT study data from Norway shows that improving cardiorespiratory fitness by one metabolic equivalent (1 MET) reduces mortality risk by approximately 12%.
The emerging functional assessment panel includes:
- Gait speed over 4 meters—below 0.8 m/s signals elevated frailty risk regardless of age
- Chair stand test (5 repetitions)—directly reflects lower body power and sarcopenia status
- Cognitive processing speed—reaction time tasks correlate with white matter integrity and prefrontal function
- Heart rate variability (HRV)—particularly the high-frequency component reflecting parasympathetic tone
- Balance duration (single-leg stance)—each 10-second improvement associates with reduced fall risk
The synthesis matters most. A biological age 8 years younger than chronological means little if grip strength is declining and gait speed slowing. Conversely, excellent functional markers with elevated GDF-15 suggest hidden metabolic stress requiring investigation.
What This Means For You
- Track grip strength monthly using a calibrated dynamometer—it’s inexpensive and highly sensitive to intervention effects
- Measure HRV consistently using morning readings under standardized conditions for trend analysis
- Prioritize interventions that improve both molecular and functional markers—disconnects between the two warrant investigation
Key Points:
- Third-generation epigenetic clocks now detect intervention effects within 8 weeks, making DunedinPACE plus GrimAge2 the optimal combination for tracking rejuvenation progress
- Organ-specific proteomic aging reveals hidden vulnerabilities—approximately 20% of individuals have one organ aging 5+ years faster than others, creating targeted treatment opportunities
- Functional biomarkers must accompany molecular markers—grip strength, gait speed, and HRV provide real-world validation that cellular changes translate to capability preservation
The Road Ahead for Genomic Rejuvenation Through 2027 and Beyond
The Road Ahead for Genomic Rejuvenation Through 2027 and Beyond
The convergence of epigenetic reprogramming, precision gene therapy, and artificial intelligence-driven drug discovery is accelerating faster than even optimistic projections anticipated. We are entering what Dr. David Sinclair of Harvard Medical School calls “the decade of age reversal”—a period where interventions move from extending lifespan to genuinely restoring youthful function at the cellular level.
The implications for those committed to radical longevity are profound. By 2027, several therapeutic approaches currently in Phase I/II trials will likely reach clinical availability, fundamentally changing what “anti-aging medicine” means.
Partial Cellular Reprogramming Enters Human Trials
The landmark work of Shinya Yamanaka, whose four transcription factors earned the 2012 Nobel Prize, has spawned an entirely new therapeutic category. Companies like Altos Labs, backed by $3 billion in funding, are racing to deliver partial reprogramming that resets epigenetic age without erasing cellular identity.
Dr. Juan Carlos Izpisúa Belmonte’s pioneering mouse studies demonstrated that cyclic expression of Yamanaka factors could extend lifespan by 15% while reversing age-related tissue damage. The challenge now is precision delivery—ensuring factors activate in controlled pulses rather than continuously, which risks teratoma formation.
- Altos Labs is developing proprietary delivery systems targeting specific tissues
- NewLimit, founded by Brian Armstrong, focuses on liver and immune cell reprogramming
- Turn Biotechnologies has demonstrated mRNA-based factor delivery with tight temporal control
💡 Quick Fact: A 2024 study from Rejuvenate Bio showed partial reprogramming in aged mice restored 50% of youthful gene expression patterns in cardiac tissue within just six weeks of treatment.
What This Means For You
- Monitor clinical trial registrations at ClinicalTrials.gov for partial reprogramming studies—early access programs may emerge by 2026
- Optimize your epigenetic landscape now through evidence-based interventions, creating a better “starting point” for future therapies
- Consider biobanking young cells—mesenchymal stem cells and PBMCs stored today preserve options for autologous treatments emerging tomorrow
Gene Therapy Targeting Core Aging Pathways
Beyond reprogramming, single-gene interventions targeting master regulators of aging are advancing rapidly. Dr. George Church’s lab at Harvard has identified 45 genetic variants protective against age-related diseases, several now being developed as gene therapies.
Telomere extension therapy using hTERT delivery has shown promising safety data in compassionate use cases. Meanwhile, Klotho gene therapy—based on the longevity-associated gene discovered by Dr. Makoto Kuro-o—demonstrated cognitive restoration in aged mice equivalent to two years of rejuvenation in a 2023 Nature Aging publication.
The convergence with delivery technology is critical:
- Lipid nanoparticles (LNPs) now achieve tissue-specific targeting with >80% accuracy
- Adeno-associated viruses (AAVs) engineered for reduced immunogenicity enable repeat dosing
- CRISPR base editing allows permanent genetic modifications without double-strand breaks
The Integration of AI-Accelerated Discovery
What would have required decades of research is now compressing into years. Insilico Medicine used AI to identify a novel senolytic compound, ISM001-055, in just 18 months—moving from target discovery to human trials faster than any previous anti-aging drug.
Machine learning platforms are now predicting:
- Optimal combination therapies matching interventions to individual aging signatures
- Novel targets within the epigenetic machinery previously invisible to traditional screening
- Safety profiles before human testing through sophisticated simulation models
Key Points:
- Partial cellular reprogramming therapies will likely reach early clinical availability by 2026–2027, with Altos Labs, NewLimit, and Turn Biotechnologies leading development
- Single-gene therapies targeting Klotho, telomerase, and protective variants offer complementary approaches to epigenetic reprogramming for comprehensive rejuvenation
- AI-accelerated drug discovery is compressing development timelines from decades to months, making 2025–2030 the most consequential period in longevity medicine history
✦ McKaizer Institute Protocol
Evidence-ranked, actionable steps distilled from the research above.
- Step 1: See the detailed protocol section above.
- Step 2: See the detailed protocol section above.
- Step 3: See the detailed protocol section above.
- Step 4: See the detailed protocol section above.
- Step 5: See the detailed protocol section above.
Leave A Comment